The DOI matches its Crossref record; 123 of the 125 references it cites were found in a registry or an index.
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Abstract
Small non-coding microRNAs (miRNAs) are instrumental in physiological processes, such as proliferation, cell cycle, apoptosis, and differentiation, processes which are often disrupted in diseases like cancer. miR-155 is one of the best conserved and multifunctional miRNAs, which is mainly characterized by overexpression in multiple diseases including malignant tumors. Altered expression of miR-155 is found to be associated with various physiological and pathological processes, including hematopoietic lineage differentiation, immune response, inflammation, and tumorigenesis. Furthermore, miR-155 drives therapy resistance mechanisms in various tumor types. Therefore, miR-155-mediated signaling pathways became a potential target for the molecular treatment of cancer. In this review, we summarize the current findings of miR-155 in hematopoietic lineage differentiation, the immune response, inflammation, and cancer therapy resistance. Furthermore, we discuss the potential of miR-155-based therapeutic approaches for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Differential expression of miRNAs has emerged to be vital regulators of MDR acquisition in HCC progression,17,18”
Citations
Cites
1 retracted
Kong, W. W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101055 · Cited by 378
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317 · cited 3×
“, the potential involvement of miRNAs in the modulation of inflammation stimuli was examined by miRNA expression analysis of 200 miRNAs [32].”
BackgroundInfluentialIdentification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023
Cited by
Sorted by citations
Items 201–216 of 216
Gao, X., Zhou, J., Wang, J., Dong, X., Chang, Y., & Jin, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-752933/v1
Zhang, Q., Wang, Z., Zhang, Z., Zhu, L., & Yang, X. (2022) · All Life · doi:10.1080/26895293.2022.2080280
Epigenetic Changes Induced by Infectious Agents in Cancer
Tristán-Flores, F. E., de la Rocha, C., Pliego-Arreaga, R., Cervantes‐Montelongo, J. A., & Silva-Martínez, G. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-62558-9_19 · Cited by 1
Shi, T.-L., Wong, L., Wang, L., You, Z.-H., Yu, C.-Q., Jiang, C., & Liang, S.-Z. (2024) · Research Square · doi:10.21203/rs.3.rs-5400619/v1
Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review
Yao, X., Wang, Z., Zhang, Y., Shao, Z., Lian, J., Chen, Y., Lin, X., Qu, D., & Yang, W. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1713597
Li, X., He, J., Ren, X., Zhao, H., & Zhao, H. (2020) · Figshare · doi:10.6084/m9.figshare.13468107
Dogra, P., Shinglot, V., Ruiz-Ramírez, J., Cave, J., Butner, J. D., Schiavone, C., Duda, D. G., Kaseb, A. O., Chung, C., Koay, E. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26757034
Gao, X., Zhou, J., Wang, J., Dong, X., Chang, Y., & Jin, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16865015
Jiao, Y., Mi, S., Li, X., Liu, Y., Han, N., Xu, J., Liu, Y., Li, S., & Guo, L. (2023) · Figshare · doi:10.6084/m9.figshare.24715436
Miroshnichenko, S. K., Demirel, R., Moralev, A. D., Almieva, O., Markov, A. V., Burakova, E., Stetsenko, D., Maslov, M. A., Vlassov, V. V., & Аркадьевна, З. М. (2025) · Biomedicines · doi:10.3390/biomedicines13123118
miR-141-5p regulates cervical cancer malignant progression by targeting MRVI1
JIANG, L., Liu, C., Xu, X., Zhao, Y., & Yuan, D. (2026) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.25.03244-4
Unveiling the epigenetic landscape of AMPK regulation in cancer metabolism
Dongre, S., Jaiswal, A., Chaudhary, M., Soni, N., & Bissa, B. (2026) · Gene · doi:10.1016/j.gene.2026.150062
Role of exosomal microRNAs in anticancer drug resistance and tumor angiogenesis
Banerjee, A., Banerjee, S., Singh, A. K., & Singh, R. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36390-0.00002-6
Understanding the microRNA signature associated with Reye’s syndrome
Puhan, A., Tripathy, S., Behera, J. K., & Bhattacharya, M. (2026) · PROTOPLASMA · doi:10.1007/s00709-026-02226-6
A systematic review on the possible role of microRNA-155 in cancer treatment
Ravichandran, S. N., Banerjee, A., Parnigotto, P. P., Pathak, S., & Barbon, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1885427
Chengzhi, W., Yifan, L., Songwei, L., Mengmeng, D., Keying, Z., & Huan, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1937363
Metadata
- Authors
- Bayraktar, R., & Van Roosbroeck, K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Bayraktar, Recep
- Venue
- Cancer and Metastasis Reviews
- Published
- 2017-12-27
- Volume
- 37
- Issue
- 1
- Pages
- 33-44
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2779116051
- Cited by
- 216
- References
- 125
- Citations by year
- 2026: 9 · 2025: 24 · 2024: 30 · 2023: 32 · 2022: 36 · 2021: 32 · 2020: 27 · 2019: 17 · 2018: 9
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer and Metastasis Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lauri Strauss Leukemia Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-155, microRNA, chemoresistance, miRNA-based therapy, hematopoietic differentiation, immune response, inflammation, carcinogenesis, cancer therapy resistance
- MeSH terms
- Animals, Humans, Neoplasms, Oncogenes, Radiation Tolerance, Biomarkers, Tumor, Genetic Therapy, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, MicroRNAs, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
